The new National Cholesterol Education Program guidelines: Clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease

Archives of Internal Medicine

Volumn 162, Issue 18, 2002, Pages 2033-2036

  Eidelman, Rachel S ^a   Lamas, Gervasio A ^a   Hennekens, Charles H ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; DILTIAZEM; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; VERAPAMIL;

ADULT; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; FAT INTAKE; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; LIVER DYSFUNCTION; MYOPATHY; NOTE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RHABDOMYOLYSIS; RISK ASSESSMENT;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MASS SCREENING; PRACTICE GUIDELINES; PRIMARY PREVENTION; RISK ASSESSMENT; UNITED STATES;

EID: 0037078282     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.18.2033     Document Type: Note

References (23)

1. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. Rubin R. More people need cholesterol drugs: 1 in 5 US adults should be treated, new guidelines say. USA Today. May 16, 2001;Health section.
3. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. JAMA. 1997;278:313-321.
4. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
5. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease risk factor categories. Circulation. 1998;97:1837-1847.
6. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation. 1998;97:1095-1102.
7. Hennekens CH. Clinical and research challenges in risk factors for cardiovascular diseases. Eur Heart J. 2000;21:1917-1921.
8. Buring JE, O'Connor GT, Goldhaber SZ, et al. Decreased HDL2 and HDL3 cholesterol, ApoA-I and ApoA-II, and increased risk of myocardial infarction. Circulation. 1992;85:22-29.
9. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
10. Jacobson TA, Griffiths GG, Varas C, et al. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data: National Health and Nutrition Examination Survey. Arch Intern Med, 2000;160:1361-1369.
11. Hennekens CH. Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease. Clin Cardiol. 2001;24(suppl 7): 112-115.
12. Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics Co Inc; 2001.
13. MacCarthy EP. Important Drug Warning, Bayer, Re: Market Withdrawal of Baycol (Cerivastatin) [flyer]. West Haven, Conn: Bayer Pharmaceutical Division; August 8, 2001.
14. Bottorff M, Hansten P. Long-term clinical safety of hepatic hydroxymethyl glutaryl coenzyme reductase inhibitors. Arch Intern Med. 2000;160: 2273-2280.
15. Ducobu J. Lipids and AIDS [in Dutch]. Rev Med Brux. 2000;21:11-17.
16. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16: 569-577.
17. 2002 Drug Topics Red Book. Montvale, NJ: Medical Economics/Thomson Healthcare Inc; 2001.
18. Levine RS, Foster JE, Fullilove RE, et al. Black-white inequalities in mortality and life expectancy from 1933-1999: implications for Healthy People 2010. Public Health Rep. 2001;116:474-483.
19. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
20. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil forthe secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341: 410-418.
21. Ridker PM, Cushman M, Stampfer MJ, Tracey RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
22. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass pattern and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
23. Pearson T, Lauora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.